Eisai

Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen
Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen
Reuters
Biogen
Eisai
Japan
Leqembi
Alzheimer's disease
Flag link:
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
melanoma
colorectal cancer
non-small cell lung cancer
Flag link:
Eisai launches digital dementia specialist company
Eisai launches digital dementia specialist company
Pharmaphorum
Eisai
digital health
dementia
Theoria Technologies
Flag link:
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
BioSpace
Alzheimer's disease
Eli Lilly
Biogen
Eisai
Leqembi
donanemab
Flag link:
Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer
Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer
BioSpace
Merck
Eisai
Keytruda
Lenvima
clinical trials
head and neck cancer
Flag link:
New Alzheimer’s drug raises hopes — along with questions
New Alzheimer’s drug raises hopes — along with questions
Medical Marketing and Media
FDA
Alzheimer's disease
Eisai
Biogen
Leqembi
Flag link:
The real costs of the new Alzheimer’s drug, most of which will fall to taxpayers
The real costs of the new Alzheimer’s drug, most of which will fall to taxpayers
Medical Marketing and Media
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version
After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version
Fierce Pharma
Eisai
Biogen
Leqembi
FDA
Alzheimer's disease
subcutaneous drug delivery
Flag link:
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Clinical Trials Arena
Eli Lilly
donanemab
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
Medicare’s Proposed Coverage for Alzheimer’s Scan Could Be Boon for Eisai/Biogen
Medicare’s Proposed Coverage for Alzheimer’s Scan Could Be Boon for Eisai/Biogen
BioSpace
CMS
Alzheimer's disease
Eisai
Biogen
PET scans
Flag link:
Why new Alzheimer’s drugs are in for a tepid launch
Why new Alzheimer’s drugs are in for a tepid launch
Medical Marketing and Media
Alzheimer's disease
drug launches
Biogen
Eisai
Leqembi
Flag link:
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
Motley Fool
Biogen
Eisai
Leqembi
Alzheimer's disease
Flag link:
How will the price of Eisai and Biogen's Leqembi impact Medicare? Sen. Sanders wants to know
How will the price of Eisai and Biogen's Leqembi impact Medicare? Sen. Sanders wants to know
Fierce Pharma
Eisai
Biogen
Leqembi
drug pricing
Medicare
Alzheimer's disease
Flag link:
Eisai's US CEO and Alzheimer's lead Ivan Cheung telegraphs retirement days after Leqembi's full FDA nod
Eisai's US CEO and Alzheimer's lead Ivan Cheung telegraphs retirement days after Leqembi's full FDA nod
Fierce Pharma
Eisai
Alzheimer's disease
Leqembi
Ivan Cheung
Flag link:
Leqembi Wins Full FDA Approval as First Anti-Amyloid Antibody for Alzheimer’s
Leqembi Wins Full FDA Approval as First Anti-Amyloid Antibody for Alzheimer’s
BioSpace
Biogen
Eisai
Leqembi
FDA
Alzheimer's disease
Flag link:
9 Highly Anticipated FDA Decisions in Second Half of 2023
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
SAGE Therapeutics
zuranolone
postpartum depression
major depressive disorder
Roche
Tecentriq
non-small cell lung cancer
CRISPR Therapeutics
Bluebird Bio
lovo-cel
exa-cel
BrainStorm Cell Therapeutics
NurOwn
Flag link:
5 FDA decisions to watch in the third quarter
5 FDA decisions to watch in the third quarter
BioPharma Dive
FDA
SAGE Therapeutics
Biogen
zuranolone
Eisai
Leqembi
Sanofi
AstraZeneca
nirsevimab
Iveric Bio
Zimura
Alnylam
Onpattro
Flag link:
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
Motley Fool
Biogen
Eisai
Alzheimer's disease
FDA
Leqembi
Flag link:
Does This Signal Trouble for Biogen's New Alzheimer's Drug?
Does This Signal Trouble for Biogen's New Alzheimer's Drug?
Motley Fool
Eisai
Biogen
Leqembi
Alzheimer's disease
Europe
Flag link:
On the Cusp of Full Approval, Leqembi’s Rollout Could Face Challenges
On the Cusp of Full Approval, Leqembi’s Rollout Could Face Challenges
BioSpace
Eisai
Biogen
Alzheimer's disease
FDA
Leqembi
Flag link:

Pages